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ABSTRACT 43 
Purpose: To develop a core set of clinical indicators that enables international benchmarking 44 
of localised prostate cancer management using data available in the TrueNTH Global 45 
Registry. 46 
 47 
Materials and Methods: An international expert panel completed an online survey and 48 
participated in a face-to-face meeting. Participants included urologists (n=3), radiation 49 
oncologists (n=3), psychologists (n=2), medical oncologist (n=1), nurse (n=1) and an 50 
epidemiologist (n=1) with prostate cancer expertise from seven countries. Current guidelines 51 
on prostate cancer treatment and potential quality indicators were identified from a literature 52 
review. These potential indicators were refined and developed through a modified Delphi 53 
process, during which each panellist independently and repeatedly rated each indicator based 54 
on its importance (satisfying the indicator demonstrates a provision of high-quality care) and 55 
feasibility (likelihood that data being used to construct the indicator could be collected at a 56 
population level). The main outcome measure was items with panel agreement (disagreement 57 
index<1), median importance ≥8.5 and median feasibility ≥9. 58 
 59 
Results and Conclusions: Thirty-three indicators received endorsement from the expert 60 
panel. These 33 prostate cancer quality indicators assess care relating to diagnosis (n=7), 61 
primary treatment (n=7), salvage treatment (n=1) and health outcomes (n=18).  62 
 63 
In summary, we have developed a set of quality indicators for measuring prostate cancer care 64 
from numerous international evidence-based clinical guidelines. These indicators will be pilot 65 
tested in the TrueNTH Global Registry. Reports comparing indicator performance will 66 
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subsequently be distributed to participating sites, with the purpose of improving the 67 
consistency and quality of prostate cancer management on a global basis. 68 
  69 
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BACKGROUND 70 
 71 
Evidence-based practice, which promotes the judicious conscientious use of scientific 72 
evidence to inform clinical management, is a pillar of modern medicine. Innumerable best 73 
practice guidelines discussing the management of localised prostate cancer (PCa) have been 74 
published, aiding practitioners to understand the most appropriate management for the large 75 
number of men diagnosed with this disease each year. 76 
 77 
Despite the accessibility of these guidelines, practice commonly varies from that 78 
recommended. For example, the rate of patients in the United States with high-risk PCa 79 
receiving first-line radiotherapy with concomitant androgen deprivation therapy (ADT), 80 
which is a National Comprehensive Cancer Network (NCCN) and European Association of 81 
Urology (EAU) recommendation, ranged from 58% to 75% and was declining1. Significant 82 
discrepancies in PCa care among different geographical regions have also been evidenced2, 3.  83 
 84 
Quality indicators (QIs) are explicitly defined, consensus-based, measurable items which 85 
enable comparison and act as a catalyst for improvement4. Indicators are currently being used 86 
to monitor PCa quality of care by the RAND Health Science Program in the United States5, 87 
the National Prostate Cancer Register of Sweden6, the prostate cancer centers certification 88 
program by the German Cancer Society7 and the Prostate Cancer Outcomes Registry in 89 
Australia and New Zealand8. It remains a challenge to demonstrate that outcomes for men 90 
improve as a result of performance assessment against QIs, however promising examples 91 
exist. Dissemination of benchmarking provider performance to urologists in Victoria, 92 
Australia demonstrated improved adherence to three QIs over the 5-year study period9. In 93 
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Sweden, there was improvement in six out of nine QIs, including the number of men with 94 
very-low-risk disease undergoing AS, over a 3-year period6.  95 
 96 
The existence of numerous PCa registries and the development of international consensus 97 
minimum datasets for localised PCa by the International Consortium for Health Outcome 98 
Measures (ICHOM)10 provides an opportunity to harness existing infrastructure and 99 
investment to establish core QIs. The TrueNTH Global Registry11 has modelled clinical and 100 
patient-reported data on the ICHOM standard set for localised PCa10. This will provide a 101 
platform where data can be used to evidence performance against QIs, which will provided to 102 
participating organisations and allow comparison amongst peers. The paper describes an 103 
effort to identify a consensus set of QIs to benchmark PCa management among international 104 
groups contributing to the registry. 105 
 106 
METHODS 107 
We used a modified Delphi process, which combines scientific evidence with the 108 
professional expert opinion12. Approval was gained from the Monash University Human 109 
Research Ethics Committee (2016-5551-5405). 110 
 111 
Panel composition and consent process 112 
The panel was composed using purposive sampling of fifteen international leaders of 113 
Movember-funded PCa research activities. These invited individuals have expertise in PCa 114 
and were from countries involved in the TrueNTH Global Registry. Informed consent was 115 
obtained at the project’s commencement.  116 
 117 
Literature Review 118 
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A range of international guidelines for the diagnosis and management of localised PCa, 119 
restricted to those published in English, were reviewed (Supplementary Table 1). We also 120 
evaluated grey literature on indicator initiatives in available PCa programs (Supplementary 121 
Table 1) to identify potential indicators not stated in the guidelines. These guidelines and 122 
recommendations were collated. Study Investigators (FS, JZ, LDS, JM and SE) derived 123 
indicators from these recommendations and determined if they could be objectively measured 124 
and developed within the limitations of the registry dataset.  125 
 126 
Online survey 127 
In the first-round, panellists were asked to complete an online survey reviewing the refined 128 
list of proposed indicators. To maintain anonymity, each participant was given an 129 
identification number which was known only by two Investigators (FS and JZ). The 130 
indicators were presented chronologically, in line with the PCa management pathway (page 6, 131 
Supplementary File 1). Panellists received an accompanying document with each indicator’s 132 
source, supporting strength of evidence and proposed construct (numerator and denominator) 133 
(page 22, Supplementary File 1). They were asked to rate each indicator’s importance on a 9-134 
point Likert scale (1= not important to 9= very important). Importance was defined as the 135 
extent to which satisfying the indicator demonstrated a provision of high-quality care and that, 136 
conversely, not meeting the indicator signalled poor-quality care. Panellists were asked to 137 
respond with ‘unable to comment’ if they could not give an informed professional opinion. 138 
They were encouraged to suggest modifications or propose new indicators. 139 
 140 
To establish a consistent method of measuring indicators, panellists were asked to select a 141 
single risk stratification method which would be used to define low, intermediate and high-142 
risk PCa. 143 
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Expert panel meeting 145 
Using the first-round survey results, the median importance (MI) and disagreement index (DI) 146 
was calculated for all proposed indicators (Table 1). The MI ranged from 1-9. The DI is a 147 
continuous scale used to describe dispersion of ratings by panellists12 (Supplementary Table 148 
2). A DI of 0 represents complete agreement among panellists while a DI≥1 has been 149 
determined by RAND to indicate disagreement12. ‘Unable to comment’ responses were 150 
excluded from the calculations. 151 
 152 
A traffic light system, with the colours green, amber and red, was used to differentiate 153 
between indicators with the greatest support and the greatest level of disagreement amongst 154 
panellists. Indicators with the greatest support, defined as a MI≥7 and DI<1, were categorised 155 
as green. All indicators with panel disagreement (DI≥1) were amber. Indicators with panel 156 
agreement (DI<1) and the lowest level of support (MI<7) were classified as red. This system 157 
is summarised in Table 1. 158 
 159 
[Table 1 about here] 160 
 161 
In keeping with the RAND Delphi process12, an in-person meeting with an independent 162 
moderator (NW) was conducted to discuss survey results. All indicators from the first-round 163 
were addressed with a focus on those categorised as amber (MI>7, DI≥1). Following 164 
discussion of each indicator, panellists independently re-rated importance and also feasibility 165 
using the same 9-point Likert scale from the first-round (1= not important and 9= very 166 
important; 1= not feasible and 9= definitely feasible). Feasibility was defined as the 167 
likelihood that the data being used to construct the indicator could be collected at a 168 
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population level and be considered both reliable (able to be consistently produced) and valid 169 
(measure what it ought to measure). This was completed using their identification numbers 170 
either online or on paper, depending on individual preference.  171 
 172 
Final review of indicators 173 
Following the panel meeting, indicators with MI≥7, median feasibility (MF) ≥7 and DI<1 174 
were presented to the panellists for review. With the final number of indicators restricted for 175 
practicality, they were asked to evaluate the cut-off point, in terms of MI and MF, for 176 
inclusion into the global registry. 177 
 178 
RESULTS 179 
11/15 (82%) of invited panellists accepted the invitation to participate in the study.  Table 2 180 
provides a summary of their specialisation and country of practice.  181 
 182 
[Table 2 about here] 183 
 184 
The literature review revealed 352 potential indicators (76 diagnosis, 226 treatment and 50 185 
outcomes) (Figure 1). Using Donabedian’s4 framework for classifying quality of care, this 186 
comprised of 18 structure, 294 process and 40 outcome measures.  Of these, 229 were 187 
removed because they were not able to be constructed from the global registry dataset. The 188 
remaining 123 indicators were rated in the online survey. Results demonstrated that there was 189 
agreement (DI<1) among panellists that 70/123 indicators were very important (MI≥7) and 190 
that 4/123 (3%) were not important (MI<7). There was disagreement among panel members 191 
(DI≥1) for the remaining 49/123 (40%). 192 
 193 
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[Figure 1 about here] 194 
 195 
The expert panel meeting was undertaken over 10 hours with nine panellists. Two panellists 196 
who voted were unable to participate. The panel reached consensus that the NCCN risk 197 
prediction model13 would be used to stratify patients. Following discussion of the 123 198 
indicators, 53 indicators were maintained without modification, 36 indicators maintained with 199 
modifications, 34 indicators removed and 6 indicators added. The number of indicators with 200 
disagreement reduced from 49 to 17. The panel retained all proposed structural indicators 201 
(100%), 35/78 proposed process measures (45%) and 18/43 proposed outcome indicators 202 
(42%). 203 
 204 
For final review, 55 indicators with MI≥7, MF≥7 and DI<1 for both constructs were 205 
presented to the stakeholders (Table 3).  Most indicators (28/55 (51%)) were treatment-206 
related, 18/55 (33%) were outcome measures and 9/55 (16%) concerned diagnosis. The 207 
indicator, ‘men with high-risk localised PCa do not receive AS’ was removed as it was 208 
measured by ‘men with high-risk localised PCa receive active treatment within 12 months’. 209 
Three indicators (‘PSA level is taken post-surgery’, ‘PSA level is taken post-radiotherapy’, 210 
‘PSA level is taken post-ablation therapy’) were merged into ‘PSA level is taken at 12 211 
months after the start of active treatment’. Of the remaining 52 indicators (Supplementary 212 
Table 3), the consensus was to prioritise those that received MI≥8.5, MF≥9 and DI<1 for both 213 
constructs. This resulted in a total of 33 QIs for the implementation set (7 diagnosis, 8 214 
treatment and 18 outcome); this list is presented in Table 4. 215 
 216 
[Table 3 about here] 217 
 218 
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[Table 4 about here] 219 
 220 
DISCUSSION 221 
Of the 123 indicators presented to the panel, a set of 33 evidence- and consensus-based QIs 222 
were selected to initiate international PCa care benchmarking. This set of indicators addresses 223 
all major aspects of PCa management – diagnosis, intervention and patient-reported outcomes 224 
– and identifies areas of care which are potential targets for improving service.  225 
 226 
Pre-treatment QIs which rated high in importance and feasibility included measurement of 227 
PSA level at diagnosis, documentation of clinical T-stage (cT) and use of imaging for staging. 228 
Previous cohort studies have demonstrated unnecessary and costly routine bone scans and 229 
computed tomography scans being performed for men with asymptomatic low-risk disease14, 230 
15
. Conversely, there remains suboptimal use in high-risk men16 despite recommendations13, 17. 231 
Feedback of QIs regarding the documentation of cT stage18 and bone scans for low-risk 232 
disease19 have been shown to improve compliance with guidelines. 233 
 234 
There was discussion among the Delphi panel on the use of multi-parametric magnetic 235 
resonance imaging (mpMRI) for pre-treatment staging. Whilst the panel regarded digital 236 
rectal examination (DRE) as the mainstay of practice, there was recognition of evidence 237 
demonstrating the superiority of mpMRI in detecting extra-capsular extension, seminal 238 
vesicle invasion20 and informing treatment planning20, 21. However, in the absence of clear 239 
guidelines on the optimal staging protocol, both DRE and MRI were considered appropriate 240 
for assigning a disease stage. 241 
 242 
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A treatment indicator which received the greatest support was curative treatment being 243 
instigated in high-risk patients within 12 months. Although multimodality therapy is often 244 
recommended for high-risk PCa13, 22, 23, the National Prostate Cancer Audit in UK reported 245 
that 39% of men with high-risk disease were undertreated with ADT monotherapy24. 246 
Likewise, the CaPSURE database demonstrated that 41% of high-risk patients received ADT 247 
monotherapy25. No age restrictions were placed on this indicator because elderly men with 248 
good quality-of-life may be suitable candidates for radical treatment17. Men who die within 249 
12 months of diagnosis will be excluded as they are likely unsuitable candidates for active 250 
intervention. On the contrary, the challenge faced by men with low-risk disease is 251 
overtreatment and the morbidity of treatment-related complications. Active surveillance (AS) 252 
has been increasingly adopted as a standard approach for these men6, 9. There was unanimous 253 
consensus that the number of low-risk men on AS should be reported and that appropriate AS 254 
monitoring with a repeat prostate biopsy or MRI scan within 13 months of the diagnostic 255 
biopsy should also be measured. 256 
 257 
Measurement of PSA level post-treatment was strongly advocated as it is the primary tool for 258 
measuring efficacy of treatment, detecting early signs of recurrence and need for salvage 259 
therapy17, 26. Other post-treatment risk assessment measures included 30-day mortality post-260 
radical prostatectomy (RP), positive margins rates post-RP and biochemical recurrence post-261 
RP and radiotherapy. Biochemical recurrence27 was defined by our working group as 262 
PSA≥0.2 ng/mL post-RP and ≥2.0 ng/mL rise above nadir post-radiotherapy. The panel did 263 
not endorse biochemical recurrence post-ablation therapy as an indicator due to the current 264 
lack of an agreed definition17, 28. Instead, the rate of men who received radical or systemic 265 
treatment 18 months post-ablation therapy was nominated as a surrogate measure. 266 
 267 
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Routine collection of patient-reported outcomes (PROMs) has been shown to improve 268 
quality-of-life29, survival and lessen future hospitalisations30. In addition to EPIC-26, 269 
ICHOM recommended including one question from EORTC QLQ-PR25#50 and two 270 
questions from the Use of Sexual Medication/Devices to improve the interpretability of the 271 
sexual function domain from the EPIC-2610. During the panel meeting, the measurement of 272 
pre- and post-treatment urinary, bowel, and sexual domains scores (QI 28-33, Table 4) were 273 
initially dropped in favour of indicators which assessed whether the survey instruments were 274 
administered at baseline and 12 months post-treatment (QI 22-27, Table 4). However, they 275 
were reinstated during the final review when it was recognised that merely collecting the 276 
EPIC-26 survey was inadequate and that it was important to understand the attributes of 277 
health services where patient reported good quality-of-life scores.   278 
 279 
This study had a number of noteworthy limitations. A substantial proportion of 280 
recommendations were precluded because they could not be objectively measured or 281 
captured by the global registry dataset. This most heavily impacted structural indicators, such 282 
as the frequency of multidisciplinary meetings (MDM), representation of every discipline at 283 
MDM, availability of specialist services including psychological counselling and uro-284 
oncology nurses.  The use of the word ‘offer’17, 22 in patient-centred recommendations was 285 
also difficult to translate into measurable indicators. The inherent nature of the Delphi 286 
process means there is non-random selection of a small non-representative sample of 287 
panellists. The ratings are heavily influenced by personal experience and the availability of 288 
resources at different institutions. It is acknowledged that with a different composition of 289 
panellists, the final set of indicators could have been significantly altered. It is also 290 
recognised that there is a current lack of evidence demonstrating that these QIs will reduce 291 
PCa-specific survival. 292 
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 293 
The major strengths of this project included the heterogeneity of the panel, with 11 experts 294 
from seven different countries bringing important local perspectives to the discussion. The 295 
panel was facilitated by an independent experienced moderator to mitigate the probability of 296 
conversation being dominated by a few vocal participants. Indicators were constructed based 297 
on a pre-existing dataset, providing the opportunity for reports to be developed immediately. 298 
This project is novel in that it allows international benchmarking of PCa care and outcomes 299 
based on a common global dataset, which can act as a stimulus for improving PCa quality of 300 
care at each of the contributing sites. 301 
 302 
Further effort to develop QIs which achieved MI and MF of 7 and 8 and investigate other 303 
potential indicators which cannot be currently measured by items in the global registry 304 
dataset will follow the initial rollout. Implemented indicators may demonstrate a ‘ceiling 305 
effect’ where it is difficult to further improve practice. Emerging technology may also change 306 
PCa management and evolve best practice guidelines. Accordingly, this set of indicators will 307 
be regularly re-evaluated to ensure their continued relevance and accuracy. 308 
 309 
CONCLUSIONS 310 
This study defined a set of 33 indicators conceived on the basis of existing international 311 
 evidence-based clinical guidelines and endorsed by an international multidisciplinary expert 312 
panel. The indicators encompass the diagnosis, treatment and outcome aspects of PCa 313 
management. This set will be used to benchmark performance internationally in order to 314 
improve consistency and quality of care for men with PCa on a global basis. 315 
 316 
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Table 1: The criteria for indicator classification 
 
  
Median Importance 
  1 2 3 4 5 6 7 8 9 
Disagreement 
Index 
<1 
         
≥1 
         
 
 There is panel agreement that the quality indicator is of low importance 
 
 There is disagreement among the panel about the importance of the indicator 
 
There is panel agreement that the quality indicator is of high importance 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Table 2: Background of the specialists involved in the Delphi panel 
 
 Urology Radiation Oncology 
Medical 
Oncology Nursing 
Public 
Health Psychology TOTAL 
Australia - 1 - - 1 - 2 
Germany 1 - - - - - 1 
Ireland - 1 - - - - 1 
New 
Zealand 1 - - - - - 1 
Spain - 1 - - - - 1 
UK 1 - - 1 - 1 3 
US - - 1 - - 1 2 
TOTAL 3 3 1 1 1 2 11 
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Table 3: Distribution of indicators in the summary document for final approval 
 
  FEASIBILITY 
  7 7.5 8 8.5 9 
 
7 2 Diagnosis 
2 Primary Tx - 
Other 
1 Primary Tx - 
RT 
  
8 
2 Primary Tx 
    - 1 RP 
    - 1 Other 
 
3 Primary Tx 
    - 1 AS 
    - 2 RP 
1 Primary Tx - 
RT 
5 Primary Tx 
    - 2 RP 
    - 3 RT 
1 Salvage Tx 
9 
1 Primary Tx - 
RT 
1 Primary Tx - 
AS 
 
2 Primary Tx - 
AS 
7 Diagnosis 
8 Primary Tx 
   - 1 AS 
   - 2 RP 
   - 3 RT 
   - 2 Other 
1 Salvage Tx 
18
╪
 Outcomes 
 
╪6 indicators added (QI 28-33, Table 4)  
 
Tx = Treatment; RP = Radical Prostatectomy; RT = External Beam Radiotherapy (EBRT)/ 
Brachytherapy; AS = Active Surveillance; WW = Watchful Waiting; QI = Quality Indicator 
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Table 4: Implementation set of indicators selected 
Indicator Numerator Denominator Exclusion Criteria Reporting 
Time Point 
Sources 
DIAGNOSIS    
1 Initial investigations of a male 
with localised PCa include 
measurement of PSA level 
Number of men with 
PSA level taken at 
diagnosis 
 
Note: PSA at diagnosis is 
PSA level taken within 
180 days prior to or up to 
date of diagnosis. 
Number of men 
with PCa 
Men diagnosed via 
TURP or TURBT or 
biopsy taken using 
technique other than 
TRUS or 
transperineal or 
technique not stated. 
Post diagnosis 
and pre-
treatment╤  
- Alberta Health 
Services 2015 1 
- NCCN 2017 2 
- VIC OCP 2015 3 
2 T category/stage (DRE or MRI) 
is documented prior to treatment 
for localised PCa 
Number of men with PCa 
who had T 
category/stage 
documented 
Number of men 
with PCa 
 Post diagnosis 
and pre-
treatment╤ 
- VIC OCP 2015 3 
3 In men with high risk localised 
PCa, nodal staging using CT, 
MRI or PET is performed 
Number of men with 
high risk PCa who 
underwent CT scan, MRI 
scan or PET scan 
Number of men 
with high risk 
PCa 
 
 Post diagnosis 
and pre-
treatment╤ 
- EAU 2016 4 
- ESMO 2015 5 
- NCCP 2015 6 
- NZ PCT 2013 7 
4 In men with high risk localised 
PCa, perform metastatic 
screening using a CT/MRI and a 
bone scan 
Number of men with 
high risk PCa who 
underwent a CT/MRI 
and a bone scan 
Number of men 
with high risk 
PCa 
 Post diagnosis 
and pre-
treatment╤ 
- Alberta Health 
Services 2015 1 
- EAU 2016 4 
5 In men with intermediate risk 
localised PCa, a bone scan is not 
conducted 
Number of men with 
intermediate risk PCa 
who did not have a bone 
scan 
Number of men 
with intermediate 
risk PCa 
 
Men with 4+3 
disease 
Post diagnosis 
and pre-
treatment╤ 
- NCCS 2013 8 
6 In men with low risk localised 
PCa, a bone scan is not 
conducted 
Number of men with low 
risk PCa who did not 
have a bone scan 
Number of men 
with low risk PCa 
 Post diagnosis 
and pre-
treatment╤ 
- EAU 2016 4 
- NICE 2014 9 
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7 In men with low risk localised 
PCa, a CT is not conducted 
Number of men with low 
risk PCa who did not 
have a CT scan 
Number of men 
with low risk PCa 
 
 Post diagnosis 
and pre-
treatment╤ 
- Alberta Health 
Services 2015 1 
- EAU 2016 4 
- NICE 2014 9 
PRIMARY TREATMENT    
8 For pN0 men undergoing RP, 
adjuvant ADT is not given 
Number of men who had 
RP with pN0 and did not 
receive adjuvant ADT 
 
Note: Adjuvant ADT is 
defined as ADT within 6 
months of RP 
Number of men 
who had RP with 
pN0 
 Post primary 
RP╤ 
- EAU 2016 4 
9 Men with localised PCa who are 
undergoing radical EBRT receive 
a minimum dose of 74Gy in 1.8 
– 2.0 Gy standard fractionation 
or the equivalent hypo-
fractionated dose, 60Gy in 3.0 
Gy fractions 
Number of men 
undergoing EBRT with 
curative intent who 
receive dose ≥74Gy in 
1.8 – 2.0 Gy fractional 
doses OR ≥60 Gy in 3.0 
Gy fractions 
Number of men 
undergoing 
EBRT 
 Post primary 
EBRT╤ 
- EAU 2016 4 
- NICE 2016 9 
10 Men with low risk localised PCa 
receive AS 
Number of men with low 
risk prostate cancer and 
on AS 
Number of men 
with low risk PCa 
 Post diagnosis╤ - BAUS 2013 10 
- Cancer Care 
Ontario 2014 11 
- NZ PCT 2013 7 
11 For men on AS, MRI or repeat 
biopsy is performed within 13 
months of the diagnostic biopsy 
Number of men on AS 
who had MRI or repeat 
biopsy within 13 months 
of the diagnostic biopsy 
 
Note: MRI can occur 
prior to diagnostic biopsy 
Number of men 
on AS 
Men who died within 
13 months of the 
diagnostic biopsy 
13 months post 
diagnosis 
- NCCP 2015 6 
- NICE 2016 9 
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12 Men with high risk localised PCa 
receive active treatment within 
12 months 
Number of men with 
high risk PCa who have 
had RP or EBRT or HDR 
or LDR or whole-gland 
or focal-gland ablation 
therapy within 12 months 
of diagnosis 
Number of men 
with high risk 
PCa 
Men who died within 
12 months of active 
treatment 
12 months post 
diagnosis 
- KCE 2014 12 
- NICE 2014 9 
- NZ PCT 2013 7 
13 Men with high risk localised PCa 
do not receive LDR 
brachytherapy alone 
Number of men with 
high risk PCa who 
receive LDR and primary 
EBRT 
Number of men 
with high risk 
PCa who 
received LDR 
 Post primary 
LDR╤ 
- NICE 2016 9 
14 PSA level is taken within 12 
months of active treatment 
Number of men who had 
PSA taken within 12 
months of active 
treatment  
Number of men 
on active 
treatment 
 
Note: active 
treatment 
includes RP, 
EBRT, 
brachytherapy, 
whole-gland or 
focal gland 
ablation therapy 
Men who died within 
12 months of 
diagnosis 
12 months post 
active 
treatment 
- NICE 2016 9 
SALVAGE TREATMENT    
15 Men who have salvage RT post 
RP receive a salvage RT dose 
≥66 Gy at 1.8 - 2.0 standard 
fractionation or the equivalent 
hypo-fractionated dose, ≥48 Gy 
in 3.0 Gy fractions 
Number of men who had 
salvage EBRT initiated 
post-RP with a total 
receive dose ≥66Gy in 
1.8 – 2.0 fractional doses 
or ≥48 Gy in 3.0 Gy 
fraction 
 
Number of men 
who received 
salvage EBRT 
post RP 
 Post salvage 
RT╤ 
- NCCN 2017 2 
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CLINICAL OUTCOMES    
16 Death within 30 days of RP Number of men who died 
within 30 days of the RP 
Number of men 
who had RP 
 30 days post 
RP 
- PCOR-ANZ╪ 13 
17 Men with low risk PCa who had 
a positive margin post-RP 
Number of men with low 
risk PCa and had a 
positive margin post-RP 
Number of men 
with low risk PCa 
and had a RP 
 Post primary 
RP╤ 
- PCOR-ANZ╪ 13 
18 Men with pT2 disease who had a 
positive margin post-RP 
Number of men with pT2 
disease and had a 
positive margin post-RP 
Number of men 
with pT2 disease 
and had a RP 
 Post primary 
RP╤ 
- German Cancer 
Society╪ 14 
- IPCOR╪ 15  
- NPCR╪ 16 
 
- PCOR-ANZ╪ 13 
19 Men with pT3 disease who had a 
positive margin post-RP 
Number of men with pT3 
disease and had a 
positive margin post-RP 
Number of men 
with pT3 disease 
and had a RP 
 Post primary 
RP╤ 
- IPCOR╪ 15 
- PCOR-ANZ╪ 13 
20 Biochemical recurrence at 1 year 
post RP 
Number of men who had 
RP and a PSA level 12 
month post RP ≥0.2 
ng/mL 
Number of men 
who had RP 
 1 year post 
primary RP 
- AUA 2013 17 
- EAU 2016 4 
21 Radical or systemic treatment at 
18 months post focal-gland or 
whole-gland ablation therapy 
Number of men who had 
focal-gland or whole-
gland ablation therapy 
and radical treatment or 
systemic treatment 
initiated within 18 
months post focal-gland 
or whole-gland ablation 
therapy 
 
Note: Radical treatment 
includes RP, EBRT or 
brachytherapy. Systemic 
Number of men 
who had focal-
gland or whole-
gland ablation 
therapy 
Men who died within 
18 months of focal-
gland or whole-gland 
ablation therapy 
18 months post 
primary 
ablation 
therapy 
- EAU 20164  
- Babaian et al. 
╪18
  
- Donnelly et al. ╪ 
19
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treatment refers to ADT. 
PATIENT-REPORTED OUTCOMES    
22 EPIC-26 is completed at baseline Number of men 
completed EPIC-26 
within 90 days before or 
after diagnosis 
Number of men 
with PCa 
 Post diagnosis 
and pre-
treatment╤ 
- Wei et al. ╪20 
- NPCR╪ 16 
- PCOR-ANZ╪ 13 
23 EORTC QLQ-PR25 is completed 
at baseline 
Number of men 
completed EORTC 
QLQ-PR25 within 90 
days before or after 
diagnosis 
Number of men 
with PCa 
 Post diagnosis 
and pre-
treatment ╤ 
- Van Andel et al. 
21
 
24 Utilisation of Sexual 
Medication/Devices is completed 
at baseline 
Number of men 
completed Utilisation of 
Sexual 
Medication/Devices 
questionnaire within 90 
days before or after 
diagnosis 
Number of men 
with PCa 
 Post diagnosis 
and pre-
treatment╤ 
- Miller et al. ╪ 22 
25 EPIC-26 is completed 12 months 
post diagnosis for men on AS 
and 12 months post active 
treatment for men receiving 
active treatment 
Number of men 
completed EPIC 26 
within 9-15 months of 
diagnosis (AS)/ or 9-15 
months of active 
treatment 
Number of men 
with PCa 
Men who died within 
15 months of 
diagnosis (AS)/ 
within 15 months of 
active treatment 
15 months post 
diagnosis (AS) 
/ 15 months 
post active 
treatment 
- Wei et al. ╪ 20 
- IPCOR╪ 15 
- PCOR-ANZ╪ 13 
26 EORTC QLQ-PR25 is completed 
12 months post diagnosis for 
men on AS and 12 months post 
active treatment for men 
receiving active treatment 
Number of men 
completed EORT  
QLQ-PR25 within 9-15 
months of diagnosis 
(AS)/ or 9-15 months of 
active treatment 
Number of men 
with PCa 
Men who died within 
15 months of 
diagnosis (AS)/ 
within 15 months of 
active treatment 
15 months post 
diagnosis (AS) 
/ 15 months 
post active 
treatment 
- Van Andel et al. 
╪
 
21
  
 
 
27 Utilisation of Sexual 
Medication/Devices is completed 
Number of men 
completed Utilisation of 
Number of men 
with PCa 
Men who died within 
15 months of 
15 months post 
diagnosis (AS) 
- Miller et al. ╪ 22 
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12 months post diagnosis for 
men on AS and 12 months post 
active treatment for men 
receiving active treatment 
Sexual 
Medication/Devices 
within 9-15 months of 
diagnosis (AS)/ or 9-15 
months of active 
treatment 
diagnosis (AS)/ 
within 15 months of 
active treatment 
/ 15 months 
post active 
treatment 
28 Sexual bother at 12 month 
adjusted by treatment group and 
PROMs at baseline 
Change in the mean 
score of sexual bother 
between the baseline and 
12 months by type of 
treatment 
Number of men 
with PCa 
Men who did not 
complete EPIC-26 at 
baseline or at 12 
months 
15 months post 
diagnosis (AS) 
/ 15 months 
post active 
treatment 
- PCOR-ANZ╪ 13 
- RAND╪ 23 
 
29 Urinary bother at 12 month 
adjusted by treatment group and 
PROMs at baseline 
Change in the mean 
score of urinary bother 
between baseline and 12 
months by type of 
treatment 
Number of men 
with PCa 
Men who did not 
complete EPIC-26 at 
either baseline or at 
12 months 
15 months post 
diagnosis (AS) 
/ 15 months 
post active 
treatment 
- PCOR-ANZ╪ 13 
- RAND╪ 23 
 
30 Bowel bother at 12 month 
adjusted by treatment group and 
PROMs at baseline 
Change in the mean 
score of bowel bother 
between baseline and 12 
months by type of 
treatment 
Number of men 
with PCa 
Men who did not 
complete EPIC-26 at 
either baseline or at 
12 months 
15 months post 
diagnosis (AS) 
/ 15 months 
post active 
treatment 
- PCOR-ANZ╪ 13 
- RAND╪ 23 
 
31 Sexual function at 12 month 
adjusted by treatment group and 
PROMs at baseline 
Change in the mean 
score of sexual domain 
score between baseline 
and 12 months by type of 
treatment 
Number of men 
with PCa 
Men who did not 
complete EPIC-26 at 
either baseline or at 
12 months 
15 months post 
diagnosis (AS) 
/ 15 months 
post active 
treatment 
- NPCR╪ 16 
- PCOR-ANZ╪ 13  
- RAND╪ 23 
 
32 Urinary function at 12 month 
adjusted by treatment group and 
PROMs at baseline 
Change in the mean 
score of urinary 
incontinence domain 
score between baseline 
and 12 months by type of 
treatment 
Number of men 
with PCa 
Men who did not 
complete EPIC-26 at 
either baseline or at 
12 months 
15 months post 
diagnosis (AS) 
/ 15 months 
post active 
treatment 
- NPCR╪ 16 
- PCOR-ANZ╪ 13  
- RAND╪ 23 
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Change in the mean 
score of urinary 
obstructive domain score 
between baseline and 12 
months by type of 
treatment 
 
33 Bowel function at 12 month 
adjusted by treatment group and 
PROMs at baseline 
Change in the mean of 
bowel domain score 
between baseline and 12 
months by type of 
treatment 
Number of men 
with PCa 
Men who did not 
complete EPIC-26 at 
either baseline or at 
12 months 
15 months post 
diagnosis (AS) 
/ 15 months 
post active 
treatment 
- NPCR╪ 16 
- PCOR-ANZ╪ 13  
- RAND╪ 23 
 
╤
 Quality Indicator (QI) report will be disseminated to participating sites every six months. 
 
**All risk is based on the NCCN risk classification and is assessed based on the highest primary Gleason score (if more than one biopsies were 
undertaken), the latest clinical T and the latest PSA prior to systemic or radical treatment. In the absence of a clinical T, men can be assumed to be 
low risk if Gleason score ≤6 (Grade group = 1) and PSA<10. 
 
╪Due to the lack of clinical guidelines, a range of grey literatures on indicator initiatives by prostate cancer programs were used as the basis of 
quality indicators  
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Figure 1: The number of indicators involved in each stage of refinement and elimination 
 
 
 
 
 
 
MI: Median importance 
MF: Median feasibility 
DI: Disagreement index 
AS/WW: Active surveillance/ watchful waiting 
RP: Radical prostatectomy 
RT: Radiotherapy 
 
*6 indicators added (QI 22-27, Table 4) 
during the panel meeting.  
 
⟡ 34 indicators were removed during the 
panel meeting. 
 
╤
 3 indicators related to PSA level were 
merged into ‘PSA level is taken at 12 month 
after the start of active treatment’. 
 
╪6 indicators added (QI 28-33, Table 4) 
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ABBREVIATIONS: 
ADT Androgen deprivation therapy 
AS Active surveillance 
cT Clinical T-stage 
DI Disagreement index 
DRE Digital rectal examination 
EAU European Association of Urology 
ICHOM International Consortium for Health 
Outcome Measures 
MF Median feasibility 
MI Median importance 
mpMRI Multi-parametric magnetic resonance 
imaging 
NCCN National Comprehensive Cancer Network 
NPCR National Prostate Cancer Registry of 
Sweden 
PSA Prostate specific antigen 
PCa Prostate cancer 
PCOR-ANZ Prostate Cancer Outcomes Registry in 
Australia and New Zealand 
PROMs patient-reported outcomes 
QI Quality indicator 
RP Radical prostatectomy 
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Supplementary Table 1: International guidelines and grey literature used 
Guidelines or prostate cancer programs where indicators 
were derived 
Number of 
guidelines 
References 
Australasian 5 (1-5) 
European 8 (6-13) 
American and Canadian 5 (14-18) 
Grey literature on indicator initiatives in available prostate 
cancer programs 
6 (19-24) 
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Supplementary Table 2: How the statistics are calculated 
HOW THE STATISTICS ARE CALCULATED 
 
Supplementary Table 2a: Example rating of how each panellist rated the proposed indicator 
Panellist ID #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 
Rating given  
(from 1-9) 
9 9 X 9 9 9 9 7 9 7 9 
 
Supplementary Table 2b: How the statistics, which have been used to classify indicators, are calculated 
(1) 
Measure Definition How to calculate Results 
Median An observation at the 50
th
 percentile 50
th
 percentile 9 
Lower IPR An observation at the 10
th
 percentile 10
th
 percentile 7 
Upper IPR An observation at the 90
th
 percentile 90
th
 percentile 9 
IPR The interpercentile range. It is a 
measure of dispersion of a 
distribution. 
Upper IPR – Lower 
IPR 
2 
IPRCP  The central point of IPR (Lower IPR + Upper 
IPR)/2 
8 
Asymmetry 
index 
 
 
The distance between the central 
point of the IPR and the central point 
of the 1-9 scale, i.e. 5 
Absolute value (5-
IPRCP)  
 
 
3 
IPRAS 
 
The interpercentile range adjusted 
for symmetry. It is a measure of the 
degree of asymmetry across the 9-
point scale. 
Using the numbers supplied by the 
RAND document
1
 : 
IPRAS = 2.35 + (1.5 x Asymmetry 
Index) 
= IPRr + (CFA x 
Asymmetry Index) 
6.85 
IPRr is the interpercentile range required for 
disagreement when there is perfect 
symmetry. 
CFA is the correction factor for asymmetry, 
which is a constant set at 1.5 
Disagreement 
Index (DI) 
 
 
It is a measure which shows if there 
was wide or limited dispersion of 
panellist ratings 
IPR/IPRAS 0.29 
0.29 < 1 Therefore, 
there is agreement 
If the DI is ≥ 1, then it indicates ‘extreme variation’ in ratings. The lower the DI, the 
lower the level of disagreement (i.e. the higher the level of agreement/ better 
consensus).
Note: ‘Unable to comment’ responses were excluded when calculating the statistics. 
 
 
1. Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, van het Loo M, McDonnell 
J, Vader JP, Kahan JP: The RAND/UCLA Appropriateness Method User's Manual: RAND corporation. 
2001, Available from 
https://www.rand.org/content/dam/rand/pubs/monograph_reports/2011/MR1269.pdf Accessed 
August 2017. 
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Supplementary Table 3: Final set of indicators (median importance of 7-9 and a median feasibility 
score of 7-9 and DI<1 for both constructs) 
DIAGNOSIS 
DIMENSION OF 
QUALITY OF 
CARE (1) 
1 Initial investigations of a male with localised PCa include 
measurement of PSA level 
Process 
2 T category/stage (DRE or MRI) is documented prior to treatment for localised PCa 
Process 
3 In men with high risk localised PCa, nodal staging using CT, MRI or PET/CT is performed 
Process 
4 In men with high risk localised PCa, perform metastatic screening 
using a CT/MRI and a bone scan 
Process 
5 In men with intermediate risk localised PCa, a bone scan is not 
conducted 
Process 
6 In men with high risk localised PCa, a bone scan is conducted Process 
7 In men with cT3/cT4, a bone scan is performed Process 
8 In men with low risk PCa, a bone scan is not conducted Process 
9 In men with low risk localised PCa, a CT is not conducted Process 
PRIMARY TREATMENT  
10 Men with low risk localised PCa receive AS Process 
11 Men with low risk PCa with ≤2 positive cores and minimal biopsy 
core involvement (<50% cancer per biopsy) receive AS 
Process 
12 For men on AS, MRI or repeat biopsy is performed within 13 months 
of the diagnostic biopsy 
Process 
13 In men on AS with a primary Gleason grade of 4 or 5 on repeat biopsy, active treatment is initiated 
Process 
14 Men with low risk localised Pca who received RP, nerve-sparing is performed 
Process 
15 Men with intermediate risk localised PCa who received RP, nerve-
sparing is performed 
Process 
16 For pN0 men undergoing RP, adjuvant ADT is not given Process 
17 For pN0 men undergoing RP, even those with positive margin rate, 
adjuvant ADT is not given 
Process 
18 Men with pT3 disease, positive margin(s) and detectable PSA post-RP receive EBRT within 6 months of RP 
Process 
19 
The recommended prescribed doses for adjuvant post-prostatectomy 
RT are 64–72 Gy in standard fractionation or the equivalent of 
hypofractionation 
Process 
20 
Men with localised PCa who are undergoing radical EBRT receive a 
minimum dose of 74Gy in 1.8 – 2.0 Gy standard fractionation or the 
equivalent hypo-fractionated dose, 60Gy in 3.0 Gy fractions 
Process 
21 RT should treat the prostate planning target volume with 74-78Gy Process 
22 Men with low risk localised Pca undergoing EBRT do not receive Process 
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adjuvant ADT 
23 Men with low risk localised PCa who receive LDR brachytherapy 
receive it as monotherapy 
Process 
24 Men with high risk localised PCa and undergoing EBRT receive 2-3 years of adjuvant ADT 
Process 
25 Men with high risk localised Pca who received HDR brachytherapy 
and also receive EBRT within 30 days 
Process 
26 
Men with high risk localised PCa do not receive LDR brachytherapy 
alone 
Process 
27 Men with high risk localised PCa treated with a combination of EBRT (40–50 Gy) and LDR brachytherapy receive > 1 year ADT 
Process 
28 Men treated with focal therapy have had assessment with MRI prior to focal therapy 
Process 
29 Number of men treated at the institution per year having RP Structure 
30 Number of men treated at the institution per year having EBRT or brachytherapy 
Structure 
31 Men with high risk localised PCa receive active treatment within 12 
months 
Process 
32 PSA level is taken within 12 months of active treatment Process 
SALVAGE TREATMENT  
33 In men with undetectable PSA post RP who have biochemical 
recurrence, salvage RT is not started after PSA≥ 2.0ng/mL 
Process 
34 
Men who have salvage RT post RP receive a salvage RT dose ≥66 
Gy at 1.8 - 2.0 standard fractionation or the equivalent hypo-
fractionated dose, ≥48 Gy in 3.0 Gy fractions 
Process 
OUTCOMES  
35 EPIC-26 is completed at baseline Outcome 
36 EORTC QLQ-PR25 is completed at baseline Outcome 
37 Utilisation of Sexual Medication/Devices is completed at baseline Outcome 
38 EPIC-26 is completed 12 months post diagnosis for men on AS and 12 months post active treatment for men receiving active treatment 
Outcome 
39 
EORTC QLQ-PR25 is completed 12 months post diagnosis for men 
on AS and 12 months post active treatment for men receiving active 
treatment 
Outcome 
40 
Utilisation of Sexual Medication/Devices is completed 12 months 
post diagnosis for men on AS and 12 months post active treatment 
for men receiving active treatment 
Outcome 
41 Sexual bother at 12 month adjusted by treatment group and PROMs 
at baseline 
Outcome 
42 Urinary bother at 12 month adjusted by treatment group and PROMs 
at baseline 
Outcome 
43 Bowel bother at 12 month adjusted by treatment group and PROMs 
at baseline 
Outcome 
44 Sexual function at 12 month adjusted by treatment group and PROMs at baseline 
Outcome 
45 Urinary function at 12 month adjusted by treatment group and PROMs at baseline 
Outcome 
46 Bowel function at 12 month adjusted by treatment group and PROMs 
at baseline 
Outcome 
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47 Death within 30 days of RP Outcome 
48 Men with low risk PCa who had a positive margin post-RP Outcome 
49 Men with pT2 disease who had a positive margin post-RP Outcome 
50 Men with pT3 disease who had a positive margin post-RP Outcome 
51 Biochemical recurrence at 1 year post RP Outcome 
52 Radical or systemic treatment at 18 months post focal-gland or 
whole-gland ablation therapy 
Outcome 
